FLT3 and acute myeloid leukemia: In a phase II trial of adults 61–75 years with newly diagnosed FLT3-mutated AML, crenolanib plus chemotherapy demonstrated a CR rate of 86% and was relatively well-tolerated, although four of 14 patients did require dose-reductions due to toxicity (56).